PRESS RELEASE published on 08/09/2023 at 14:30, 2 years 3 months ago Napo Pharmaceuticals, a Jaguar Health Family Company, Submits Funding Application to BARDA for Development of NP-300 Drug Candidate for Cholera-Related Diarrhea
PRESS RELEASE published on 08/08/2023 at 14:30, 2 years 3 months ago Napo Pharmaceuticals, a Jaguar Health Company, Announces Activation by FDA of Investigational New Drug (IND) Application for Crofelemer for Treatment of Microvillus Inclusion Disease
PRESS RELEASE published on 08/07/2023 at 14:30, 2 years 3 months ago Independent Study Published in Clinical Breast Cancer Shows Activity of Jaguar Health's Crofelemer for Neratinib-induced Diarrhea
PRESS RELEASE published on 08/03/2023 at 14:30, 2 years 4 months ago Jaguar Health to Present Aug 4th at Wall Street Wonders Investment Group Luncheon in NYC
PRESS RELEASE published on 08/02/2023 at 14:30, 2 years 4 months ago REMINDER: Napo Pharmaceuticals, a Jaguar Health Company, Supports Gay Men's Health with Participation in Pineapple Healthcare's "Butt Stuff Brunch with Dr. Carlton" August 5th
PRESS RELEASE published on 08/01/2023 at 14:40, 2 years 4 months ago Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)
PRESS RELEASE published on 07/27/2023 at 14:30, 2 years 4 months ago In Honor of World Nature Conservation Day, Jaguar Health Announces Planting of More Than 1.1 Million Trees in Peruvian Amazon
PRESS RELEASE published on 07/26/2023 at 14:30, 2 years 4 months ago Jaguar Health Names Principal Investigators for Clinical Trial to Support Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
PRESS RELEASE published on 07/25/2023 at 14:30, 2 years 4 months ago Napo Pharmaceuticals, a Jaguar Health Company, Supports Gay Men's Health with Participation in Pineapple Healthcare's "Butt Stuff Brunch with Dr. Carlton"
PRESS RELEASE published on 07/07/2023 at 22:15, 2 years 4 months ago Jaguar Health Reports Approval of All Proposals at 2023 Annual Meeting of Stockholders
Published on 12/05/2025 at 20:25, 44 minutes ago The Feedback Loop: Why SMX's Adoption in One Industry Accelerates Interest in All the Others
Published on 12/05/2025 at 20:15, 54 minutes ago When Proof Becomes Infrastructure, Markets Rewrite the Story (NASDAQ: SMX)
Published on 12/05/2025 at 19:50, 1 hour 19 minutes ago Gold, Rare Earth Minerals, Digital Assets: The Market Just Realized SMX Sits in All Three
Published on 12/05/2025 at 19:20, 1 hour 49 minutes ago The Multi-Sector Validation Shock: Why SMX Became Impossible for Markets to Ignore
Published on 12/05/2025 at 18:45, 2 hours 24 minutes ago Four Global Markets, One Engine: SMX Just Redefined What a Supply Chain Can Prove
Published on 12/05/2025 at 18:58, 2 hours 10 minutes ago EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:15, 2 hours 53 minutes ago Completion of merger to form Helvetia Baloise Holding Ltd
Published on 12/05/2025 at 17:46, 3 hours 22 minutes ago Booster Precision Components Holding GmbH announces the successful completion of its Written Procedure to amend and waive certain terms under the terms and conditions of the Bonds
Published on 12/05/2025 at 17:18, 3 hours 50 minutes ago La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible
Published on 12/05/2025 at 17:18, 3 hours 50 minutes ago The video of the 2024-2025 results presentation meeting on December 5, 2025, is available
Published on 12/05/2025 at 15:10, 5 hours 58 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 5 hours 58 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 7 hours 10 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
